Analysis of HLA-DRB1*0901-binding HPV-16 E7 helper T cell epitope

Journal of Obstetrics and Gynaecology Research

Volumn 30, Issue 2, 2004, Pages 120-129

  Okubo, Mitsuo ^a   Saito, Maki ^a   Inoku, Hiroki ^a   Hirata, Ranko ^a   Yanagisawa, Masami ^a   Takeda, Satoru ^a   Kinoshita, Katsuyuki ^b   Maeda, Hiroo ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b JUNTENDO UNIVERSITY   (Japan)

Author keywords

Cervical carcinoma; HLA DR; Human papillomavirus; T cell epitope; Th1; Th2

Indexed keywords

CD4 ANTIGEN; EPITOPE; HLA DR ANTIGEN; PEPTIDE; PEPTIDE E7D; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; BINDING AFFINITY; BINDING ASSAY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; HELPER CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; STIMULATION; T LYMPHOCYTE; TH1 CELL; UTERINE CERVIX CARCINOMA; WART VIRUS;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; CD4-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; DNA, VIRAL; EPITOPES; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERLEUKIN-12; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; T-LYMPHOCYTES, HELPER-INDUCER; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS;

EID: 1942453769     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2003.00171.x     Document Type: Article

References (40)

1. zur Hausen H. Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184: 9-13.
2. Nakagawa S, Yoshikawa H, Onda T, Kawana T, Iwamoto A, Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 1996; 78: 1935-1941.
3. Kato H, Nishida J, Honda T, Miyamoto S, Fujinaga K, Wake N. Chromosome alterations contribute to neoplastic progression of transformed rat embryonal fibroblasts. Cancer Genet Cytogenet 1992; 58: 39-47.
4. Li Q, Yoshioka N, Yutsudo M et al. Human papillomavirus-induced carcinogenesis with p53 deficiency in mouse: novel lymphomagenesis in HPV16 E6, E7 transgenic mice mimicking p53 defect. Virology 1998: 252: 28-33.
5. Dick FA, Dyson NJ. Three regions of the pRB pocket domain affect its inactivation by human papillomavirus E7 proteins. J Virol 2002; 76: 6224-6234.
6. Eichten A, Westfall M, Pietenpol JA, Munger K. Stabilization and functional impairment of the tumor suppressor p53 by the human papillomavirus type 16, E7 oncoprotein. Virology 2002; 295: 74-85.
7. Thompson DA, Zacny V, Belinsky GS et al. The HPV E7 oncoprotein inhibits tumor necrosis factor alpha-mediated apoptosis in normal human fibroblasts. Oncogene 2001; 20: 3629-3640.
8. Odunsi K, Terry G, Ho L, Bell J, Cuzick J, Ganesan TS. Susceptibility to human papillomavirus-associated cervical intra-epithelial neoplasia is determined by specific HLADR-DQ alleles. Int J Cancer 1996; 67: 595-602.
9. Sanjeevi CB, Hjelmstrom P, Hallmans G et al. Different HLADR-DQ haplotypes are associated with cervical intraepithelial neoplasia among human papillomavirus type-16 seropositive and seronegative Swedish women. Int J Cancer 1996; 68: 409-414.
10. Sastre-Garau X, Loste MN, Vincent-Salomon A et al. Decreased frequency of HLA-DRB1 13 alleles in French women with HPV-positive carcinoma of the cervix. Int J Cancer 1996; 69: 159-165.
11. Montoya L, Saiz I, Rey G, Vela F, Clerici-Larradet N. Cervical carcinoma. human papillomavirus infection and HLA-associated risk factors in the Spanish population. Eur J Immunogenetics 1998; 25: 329-337.
12. Apple RJ, Erlich HA, Klitz W, Manos MM, Becker TM, Wheeler CM. HLADR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genet 1994; 6: 157-162.
13. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991; 82: 524-531.
14. Nishimoto T, Matsuki K, Islam MM, Hirata R, Maeda H. Unique associations between HLA-B and HLA-DRB1*04 gene variations in Japanese. Tissue Antigens 1993; 42: 497-501.
15. Panina-Bordignon P, Tan A, Termijtelen A, Demotz S, Corradin G, Lanzavecchia A. Universally immunogenic T cell epitopes: promiscuous recognition by T cells. Eur J Immunol 1989; 19: 2237-2234.
16. Futaki G, Kobayashi H, Sato K, Taneichi M, Katagiri M. Naturally processed HLA-DR9/DR53 (DRB1*0901/DRB4*0101)-bound peptides. Immunogenetics 1995; 42: 299-301.
17. Fujisao S, Nishimura Y, Matsushita S. Evaluation of peptide-HLA binding by an enzyme-linked assay and its application to the detailed peptide motifs for HLA-DR9 (DRB1*0901). J Immunol Meth 1997; 201: 157-163.
18. Agrewala JN, Deacock S, Jurcevic S, Wilkinson R. Peptide recognition by T-cell clones of an HLA-DRB1*1501/*0901 heterozygous donor is promiscuous only between parental alleles. Human Immunol 1997; 55: 34-38.
19. Ou D, Mitchell LA, Decarie D, Tingle AJ, Nepom GT. Promiscuous T-cell recognition of a rubella capsid protein epitope restricted by DRB1*0403 and DRB1*0901 molecules sharing an HLA DR supertype. Human Immunol 1998; 59: 149-157.
20. Nobusawa E, Aoyama T, Kato H, Suzuki Y, Tateno Y, Nakajima K. Comparison of complete amino acid sequences and receptor-binding properties among 13 serotypes of hemagulutinins of influenza A viruses. Virology 1991; 182: 475-485.
21. Woulfe SL, Bono CP, Zacheis ML et al. Negatively charged residues interacting with the p4 pocket confer binding specificity to DRB1*0401. Arthritis Rheum 1995; 38: 1744-1753.
22. Hashimoto M, Kinoshita T, Yamasaki M et al. Gene frequencies and haplotypic associations within the HLA region in 916 unrelated Japanese individuals. Tissue Antigens 1994; 44: 166-173.
23. Yasukawa M, Ohminami H, Kaneko S et al. CD4 (+) cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998; 92: 3355-3361.
24. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 17-27.
25. Hohn H, Pilch H, Gunzel S et al. CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. J Immunol 1999; 163: 5715-5722.
26. Krieger JI, Karr RW, Grey HM et al. Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol 1991; 146: 2331-2340.
27. Rothbard JB, Gefter ML. Interactions between immunogenic peptides and MHC proteins. Annu Rev Immunol 1991; 9: 527-565.
28. Hammer J, Valsasnini P, Tolba K et al. Promiscus and allele-specific anchors in HLA-DR-binding peptides. Cell 1993; 74: 197-203.
29. Matsuoka T, Tabata H, Matsushita S. Monocyte are differentially activated through HLA-DR-DQ, and - DP molecules via mitogen-activated protein kinases. J Immunol 2001; 166: 2202-2208.
30. Giarre M, Caldeira S, Malanchi I, Ciccolini F, Leao MJ, Tommasino M. Induction of pRb degradation by the human papillomavirus type 16, E7 protein is essential to efficiently overcome p16INK4a-imposed G1 cell cycle Arrest. J Virol 2001: 75: 4705-4712.
31. Massimi P, Banks L. Differential phosphorylation of the HPV-16 E7 oncoprotein during the cell cycle. Virology 2000; 276: 388-394.
32. Hellung-Schonning B, Bevort M, Mikkelsen S et al. Human papilomavirus type 16, E7-regulated genes: regulation of S100P and ADP/ATP carrier protein genes identified by differential-display technology. J General Virol, 2001; 81: 1009-1015.
33. Raddrizzani L, Sturniolo T, Guenot J et al. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J Immunol 1997; 159: 703-711.
34. van Driel WJ, Ressing ME, Kenter GG et al. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. Eur J Cancer 1999; 35: 946-952.
35. Hopfl R, Heim K, Christensen N et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000; 356: 1985-1986.
36. Openshaw P, Murphy EE, Hosken NA et al. Heterogeneity of intracellular cytokine synthesis at the single-cell level in polarized T helper 1 and T helper 2 populations. J Exp Med 1995; 182: 1357-1367.
37. Murphy E, Shibuya K, Hosken N et al. Reversibility of T helper 1 and 2 populations is lost after long-term stimulation. J Exp Med 1996; 183: 901-913.
38. Doan T, Chambers M, Street M et al. Mice expressing the E7 oncogene of HPV16 in epithelium show central tolerance, and evidence of peripheral anergising tolerance, to E7-encoded cytotoxic T-lymphocyte epitopes. Virology 1998; 244: 352-364.
39. Kudo H, Matsuoka T, Mitsuya H, Nishimura Y, Matsushita S. Cross-linking HLA-DR molecules on Th1 cells induces anergy in association with increased level of cyclin-dependent kinase inhibitor p27 (Kip1). Immunol Lett 2002; 81: 149-155.
40. Hallez S, Detremmerie O, Giannouli C et al. Interleukin-12-secreting human papillomavirus type 16-transformed cells provide a potent cancer vaccine that generates E7-directed immunity. Int I Cancer 1999; 81: 428-437.